Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01191697
Title CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute

esophageal carcinoma

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma


Bevacizumab + Trastuzumab

Capecitabine + Oxaliplatin

Age Groups: adult
Covered Countries USA

No variant requirements are available.